Empowering local biomanufacturing: How to equip countries for current and future infectious disease outbreaks took place on Tuesday, May 23, 2023, at the Hotel President Wilson in Geneva.
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.
About the Global Training Hub for Biomanufacturing (GTH-B)
The COVID-19 pandemic tragically demonstrated that the international community is only safe when everyone is safe. Vaccines were a primary line of defense against COVID-19, helping some, but not all, countries overcome and build back from the pandemic. A grave imbalance of vaccine access and equity halted global recovery.
To secure vaccines and better prepare for current and future outbreaks, low- and middle-income countries around the world have seriously taken into consideration the need to build local vaccine manufacturing capacity. To meet this need, a critical resource gap is the availability of skilled, trained personnel in this highly technologically demanding field. To support these countries, the Korean Ministry of Health and Welfare (MOHW) established “Global Bio Manufacturing Workforce Training” with support from the WHO, including WHO Academy.
IVI administers training courses through this global program, the first of its kind supported by the Government of Korea, to provide essential, practical knowledge designed to strengthen professional capacity in all aspects of biomanufacturing.
Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | email@example.com